The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended)

A compound of Compounds of the formula I

$$R^{\ddagger}$$
 R^{\ddagger}
 R^{2}

in which

 R^{1} denotes H, A, Hal, $(CH_{2})_{n}$ Het, $(CH_{2})_{n}$ Ar, cycloalkyl having 3 to 7 C atoms,

CF₃, NO₂, CN, C(NH)NOH or OCF₃,

R² denotes (CH₂)_nHet, (CH₂)_nAr, cycloalkyl having 3 to 7 C atoms or CF₃,

 $R^3,\,R^4 \qquad \qquad denote \; H,\, (CH_2)_nCO_2R^5,\, (CH_2)_nCOHet,\, CHO,\, (CH_2)_nOR^5,\, (CH_2)_nHet,$

 $(CH_2)_nN(R^5)_2$, CH=N-OA, $CH_2CH=N-OA$, $(CH_2)_nNHOA$, $(CH_2)_nN(R^5)Het$,

 $(CH_2)_nCH=N-Het$, $(CH_2)_nOOOR^5$, $(CH_2)_nCH=N-Het$, $(CH_2)_n000R^5$,

(CH₂)_nN(R⁵)CH₂CH₂OR⁵, (CH₂)_nN(R⁵)CH₂CH₂OCF₃,

 $(CH_2)_nN(R^5)C(R^5)HOOOR^5$, $(CH_2)_nN(R^5)C(R^5)HOOOR^5$;

 $(CH_2)_nN(R^5)CH_2COHet$, $(CH_2)_nN(R^5)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$,

 $\underline{(CH_{2})_{n}N(R^{5})CH_{2}CH_{2}N(R^{5})CH_{2}OOOR^{5}}, \underline{(CH_{2})_{n}N(R^{5})CH_{2}CH_{2}N(R^{5})CH_{2}000R^{5}};$

(CH₂)_nN(R⁵)CH₂CH₂N(R⁵)₂, CH=CHCOOR⁵, CH=CHCH₂NR⁵Het,

CH=CHCH₂N(R⁵)₂, CH=CHCH₂OR⁵ or (CH₂)_nN(R⁵)Ar, where in each case

one of the radicals R3 or R4 denotes H,

R⁵ denotes H or A,

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms,

alkenyl or alkoxyalkyl having 2 to 10 C atoms,

Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic or

linear or branched organic radical containing one or more heteroatoms which

is unsubstituted or mono- or polysubstituted by A and/or Hal,

Ar denotes a phenyl radical which is unsubstituted or mono- or

polysubstituted by A and/or Hal, OR5, OR1, OOCR5, COOR5, CON(R5)2,

CN, NO₂, NH₂, NHCOR⁵, CF₃ or SO₂CH₃,

n denotes 0, 1, 2, 3, 4 or 5,

Hal denotes F, Cl, Br or I, and

X denotes N, or [[7]]

in the case where R1 denotes

in which R denotes H or an alkyl group having 1 to 6 C atoms, and/or R² has one of the following meanings:

in which R denotes H or an alkyl group having 1 to 6 C atoms, alternatively denotes CH,

or a salt, solvate, enantiomer, racemate, mixture of enantiomers, or a pharmaceutically

acceptable salt or solvate thereof

and salts and solvates, enantiomers, and racemates thereof and other mixtures of the enantiomers, in particular physiologically tolerated salts and solvates thereof.

- 2. (Currently Amended) A compound of Compounds of the formula I according to Claim 1, in which R¹ R! denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, -ethyl-, -n-propyl- or -n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, -dichloro- or -dicyanophenyl, 3,4,5trifluorophenyl, 3,4,5-trimethoxy- or -triethoxyphenyl, thiophen-2-yl or thiophen-3-yl.
- 3. (Currently Amended) A compound of Compounds of the formula I according to claim 1, in which R³ denotes H.
- 4. (Currently Amended) <u>A compound of Compounds of the</u> formula I according to claim 1, in which R⁴ denotes H.
- 5. (Currently Amended) A compound of Compounds of the formula I according to claim 1, in which R² denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3 or 4-fluorophenyl, 2-, 3- or 4-methyl-, -ethyl-, -n-propyl- or -n-butylphenyl, 2,3-, 2,4-, 2,5- or 2,6-difluoro- or -dicyanophenyl, thiophen-2yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, or 2- or 3-pyrazinyl.
- 6. (Currently Amended) <u>A compound of Compounds of the</u> formula I according to claim 1, in which X denotes N.
- 7. (Currently Amended) <u>A compound of formula Compounds of the formulae IA, IB, IC, ID, IE or IF and IF:</u>

$$R^{1}$$
 R^{2}
 R^{2}
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{4}
 R^{2}
 R^{4}
 R^{4

in which

R¹, R² and X have the meanings indicated in Claim 1

R¹ denotes H, A, Hal, (CH₂)_nHet, (CH₂)_nAr, cycloalkyl having 3 to 7 C atoms,

CF₃, NO₂, CN, C(NH)NOH or OCF₃,

denotes (CH₂)_nHet, (CH₂)_nAr, cycloalkyl having 3 to 7 C atoms or CF₃,

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms,

alkenyl or alkoxyalkyl having 2 to 10 C atoms,

denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic or

linear or branched organic radical containing one or more heteroatoms which

is unsubstituted or mono- or polysubstituted by A and/or Hal,

Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal, OR⁵, OOCR⁵, COOR⁵, CON(R⁵)₂, CN, NO₂, NH₂, NHCOR⁵, CF₃ or SO₂CH₃,

R⁵ denotes H or A,

n denotes 0, 1, 2, 3, 4 or 5,

Hal denotes F, Cl, Br or I, and

X denotes N, or

in the case where R¹ denotes

in which R denotes H or an alkyl group having 1 to 6 C atoms, and/or $\ensuremath{R^2}$

in which R denotes H or an alkyl group having 1 to 6 C atoms, alternatively denotes CH,

or a salt or solvate thereof.

8. (Currently Amended) A process for preparing a compound of Process for the preparation of compounds of the formula IA according to claim 7

in which R¹, R², R³, R⁴, X and A have the meanings indicated in Claim 1, and salts and solvates thereof, which is characterised in that comprising reacting a compound of the formula II

or an acid-addition salt salts thereof, in which

R¹ and X have the meanings indicated for the compound of formula IA, in Claim 1, is reacted

with a compound of the formula III

in which

A and R² have the meanings indicated for the compound of formula IA in Claim 1, and/or in that

a basic compound of the formula IA is converted into one of its salts by treatment with an acid.

9. (Currently Amended) <u>A process for preparing a compound of Process for the preparation of compounds of the formula IB according to claim 7</u>

in which R¹, R², R³, R⁴, X and A have the meanings indicated <u>for the compound of formula IB</u>, in Claim 1, and salts and solvates thereof, which is characterised in that comprising reacting a compound of the formula II

or an acid-addition salt salts thereof, in which

R¹ and X have the meanings indicated for the compound of formula IB, in Claim 1, is reacted

with a compound of the formula IV

in which

A and R² have the meanings indicated for the compound of formula IB in Claim 1, and/or in that

a basic compound of the formula IB is converted into one of its salts by treatment with an acid.

- 10. (Currently Amended) A pharmaceutical composition comprising a compound of Compounds of the formula I according to claim 1 and a pharmaceutically acceptable carrier and physiologically acceptable salts and solvates thereof as medicaments.
- 11. (Currently Amended) A method Use of the compounds of the formula I according to claim 1, and salts and solvates thereof, for the preparation of a medicament for the treatment or and prophylaxis of a disease diseases which can be influenced by the binding of a compound of the compounds of the formula I to 5 HT receptors, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 10.
- 12. (Currently Amended) A method for antagonizing a 5-HT receptor, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 10 Use of compounds of the formula I according to claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having a 5-HT receptor-antagonistic action.
- 13. (Currently Amended) A method for antagonizing a 5-HT2A receptor, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 10 Use of compounds of the formula I according to claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having a 5-HT2A receptor-antagonistic action.
 - 14. (Cancelled)
- 15. (Currently Amended) A process for preparing a pharmaceutical composition according to claim 10, comprising mixing together Process for the preparation of pharmaceutical compositions, characterised in that a compound of the formula I and a pharmaceutically acceptable carrier according to Claim 1 and/or one of its physiologically acceptable salts and/or one of its solvates is converted into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.
 - 16. (Currently Amended) <u>A method Use of compounds of the formula I</u>

according to claim 1 and/or physiologically acceptable salts or solvates thereof for the preparation of a medicament for the prophylaxis and/or treatment of psychoses, a neurological disorder disorders, amyotrophic lateral sclerosis, eating disorder disorders, such as bulimia, anorexia nervosa, of premenstrual syndrome and/or for positively influencing obsessive-compulsive disorder, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 10 (OCD).

17. (Currently Amended) <u>A compound of claim 1, Compounds of the formula I</u> in which Het is one of the following radicals:

18. (New) A compound of claim 7, in which Het is

19. (New) A compound of formula I according to claim 1

$$R^4$$
 R^3

in which

R¹ denotes H, A, Hal, (CH₂)_nHet, (CH₂)_nAr, cycloalkyl having 3 to 7 C atoms, CF₃, NO₂, CN, C(NH)NOH or OCF₃,

(CH₂)_nN(R⁵)CH₂CH₂N(R⁵)CH₂OOOR⁵, (CH₂)_nN(R⁵)CH₂CH₂N(R⁵)₂, CH=CHCOOR⁵, CH=CHCH₂NR⁵Het, CH=CHCH₂N(R⁵)₂, CH=CHCH₂OR⁵ or (CH₂)_nN(R⁵)Ar, where in each case one of the radicals R³ or R⁴ denotes H, R⁵ denotes H or A,

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, alkenyl or alkoxyalkyl having 2 to 10 C atoms,

Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic or linear or branched organic radical containing one or more heteroatoms which is unsubstituted or mono- or polysubstituted by A and/or Hal,

Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal, OR⁵, OOCR⁵, COOR⁵, CON(R⁵)₂, CN, NO₂, NH₂, NHCOR⁵, CF₃ or SO₂CH₃,

n denotes 0, 1, 2, 3, 4 or 5,

Hal denotes F, Cl, Br or I, and

X denotes N, or

in the case where R1 denotes

in which R denotes H or an alkyl group having 1 to 6 C atoms, and/or \mathbb{R}^2

in which R denotes H or an alkyl group having 1 to 6 C atoms, alternatively denotes CH,

or a pharmaceutically acceptable salt thereof.

20. (New) A compound of claim 19, in which Het is

21. (New) A compound of formula IA, IB, IC, ID, IE or IF

$$R^{1}$$
 R^{2}
 R^{2}
 R^{2}
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{4}
 R^{2}
 R^{4}
 R^{4

in which

 R^1 denotes H, A, Hal, $(CH_2)_n$ Het, $(CH_2)_n$ Ar, cycloalkyl having 3 to 7 C atoms, CF_3 , NO_2 , CN, C(NH)NOH or OCF_3 ,

R² denotes (CH₂)_nHet, (CH₂)_nAr, cycloalkyl having 3 to 7 C atoms or CF₃,

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, alkenyl or alkoxyalkyl having 2 to 10 C atoms,

Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic or linear or branched organic radical containing one or more heteroatoms which is unsubstituted or mono- or polysubstituted by A and/or Hal,

Ar denotes a phenyl radical which is unsubstituted or mono- or

polysubstituted by A and/or Hal, OR⁵, OOCR⁵, COOR⁵, CON(R⁵)₂, CN, NO₂, NH₂, NHCOR⁵, CF₃ or SO₂CH₃,

R⁵ denotes H or A,

n denotes 0, 1, 2, 3, 4 or 5,

Hal denotes F, Cl, Br or I, and

X denotes N, or

in the case where R¹ denotes

$$F \longrightarrow O_{CH_3} \longrightarrow O_{CH$$

in which R denotes H or an alkyl group having 1 to 6 C atoms, and/or $\ensuremath{\mbox{R}^2}$

in which R denotes H or an alkyl group having 1 to 6 C atoms, alternatively denotes CH,

or a pharmaceutically acceptable salt thereof.

22. (New) A compound of claim 21, in which Het is